Effects of compound Ma-ol-asal syrup on cancer-related fatigue

Phase 3

Recruiting

Conditions: eoplastic (malignant) related fatigue.
Neoplastic (malignant) related fatigue
R53.0

Registration Number: IRCT20191211045693N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

1.Age between 18- 70 years old
2. GI cancer (pathologically diagnosed)
3.Undergoing chemotherapy
4. Hemoglobin level at least 10g/dl
5. Hematocrit level at least 30% .
6. No clinical symptom of hypothyroidism
7. Visual Analogue Fatigue Scale (VAS)>=4

Exclusion Criteria

1. Heart disease with unstable conditions
2. Liver disease with unstable conditions
3. Disabling pulmonary disease
4. Positive history of hypersensitivity to honey and its compounds
5. Positive history of hypersensitivity to each component of the compound Ma-ol-asal syrup.
6. Uncontrolled pain.
7. An individual who uses treatment due to known psychiatric disease
8.Pregnancy.
9. Simultaneous use of drugs that affect fatigue.
10. kidney disease with unstable conditions
11. Severe infection
12. Serious accompanying disease.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Score of Fatigue Severity Visual Analogue Fatigue Scale. Timepoint: Week 0 (before the start of the intervention) and week 4 (after the start of the intervention). Method of measurement: Using Visual Analogue Fatigue Scale questionnaire.;Score of The Cancer Fatigue Scale. Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: The Cancer Fatigue Scale questionnaire.

Secondary Outcome Measures

Name	Time	Method
Dyspepsia. Timepoint: Week 0 (before the start of the intervention) and week 4 (after the start of the intervention). Method of measurement: Likert scale.